Literature DB >> 1328267

High-performance liquid chromatographic determination of 2',3'-didehydro-3'-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine.

J S Janiszewski1, D E Mulvana, S Kaul, K A Dandekar, R H Barbhaiya.   

Abstract

Sensitive and selective high-performance liquid chromatographic techniques have been developed for the determination of 2'-3'-didehydro-3'-deoxythymidine, d4T (BMY-27857), in human plasma and urine. The methods had linear standard curves over the concentration ranges 0.025-25.0 and 0.5-100 micrograms/ml for the plasma and urine matrices, respectively. Both methods used solid-phase extraction for isolating d4T and the internal standard, thymidine oxetane, from the biological matrix. In addition, the analytical column, mobile phase, instrumentation and chromatographic conditions used for both methods were identical. The ultraviolet absorbance of the column effluent was monitored at 266 nm. Results of analysis of quality control samples indicated that the intra-assay precision values, as measured by percent relative standard deviation, were within 12 and 3%, and accuracy samples deviated less than 10 and 5% from nominal values for the plasma and urine assays, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328267     DOI: 10.1016/0378-4347(92)80611-s

Source DB:  PubMed          Journal:  J Chromatogr


  7 in total

1.  Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis.

Authors:  D M Grasela; R R Stoltz; M Barry; M Bone; B Mangold; P O'Grady; R Raymond; S J Haworth
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

2.  Radioimmunoassay for quantitation of 2',3'-didehydro-3'-deoxythymidine (D4T) in human plasma.

Authors:  X J Zhou; H Chakboub; B Ferrua; J Moravek; R Guedj; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 3.  Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Authors:  B N Stretcher
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

4.  Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection.

Authors:  S Kaul; M W Kline; J A Church; L M Dunkle
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.

Authors:  H J Schaad; B G Petty; D M Grasela; B Christofalo; R Raymond; M Stewart
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.

Authors:  S Kaul; K A Dandekar
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex.

Authors:  C M Horton; M N Dudley; S Kaul; K H Mayer; K Squires; L Dunkle; R Anderson
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.